Uncertainties Surround Optimal Dosing of Cytarabine in AML
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
Development of prognostic tool identified a range of variables that combine to predict recurrence-free and overall survival in patients with early-stage triple-negative breast cancer.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Survey study measured factors that affect levels of distress and uncertainty in a diverse population of patients undergoing multigene hereditary cancer testing.
This phase 3 noninferiority study compared 2 formulations of pertuzumab plus trastuzumab in patients with HER2-positive early breast cancer.
This analysis identified the factors for poor long-term survival in radiotherapy (RT)-treated patients with oropharyngeal cancer (OPC).
The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.
Investigators describe the steps taken to improve clinician referrals to the facility’s outpatient rehabilitation program for patients with GI cancers.
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
Using a self-report questionnaire, investigators sought to distinct insomnia syndrome distinct from sleep disturbance in patients with cancer.